Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111752017> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W2111752017 endingPage "601" @default.
- W2111752017 startingPage "1598" @default.
- W2111752017 abstract "Administration of N-(phosphonacetyl)-L-aspartic acid (PALA) is ineffective in treating mice bearing the parent P388 leukemia line; however, such treatment becomes highly effective when a cell line, P388/ACIA, derived from P388/0 was selected for resistance to another antimetabolite, acivicin. The observed phenomenon of collateral sensitivity is associated with a significantly higher inhibition of the specific activity of carbamyl phosphate synthetase II, pyrimidine nucleoside kinases, adenine phosphoribosyl transferase, and hypoxanthine phosphoribosyl transferase in the PALA-sensitive line, P388/ACIA. Twenty-four hr following administration of PALA, 200 mg/kg, the 10% lethal dose i.p. to tumor-bearing mice, the intracellular concentrations of uridine triphosphate and cytidine triphosphate were decreased in the P388/ACIA, PALA-sensitive cells, whereas no significant change in the corresponding nucleotide pool sizes was observed in P388/0, PALA-resistant line. Moreover, the purine nucleotide pool demonstrated a significant expansion of adenosine triphosphate and guanosine triphosphate only in the P388/ACIA line following a similar treatment with PALA. It is proposed that the imbalance in the generation of pyrimidine and purine nucleoside triphosphate pools may explain the observed collateral sensitivity to PALA in P388/ACIA leukemia line." @default.
- W2111752017 created "2016-06-24" @default.
- W2111752017 creator A5012496556 @default.
- W2111752017 creator A5043198546 @default.
- W2111752017 creator A5084833290 @default.
- W2111752017 date "1983-04-01" @default.
- W2111752017 modified "2023-09-27" @default.
- W2111752017 title "Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin)." @default.
- W2111752017 cites W106534104 @default.
- W2111752017 cites W1480437404 @default.
- W2111752017 cites W1561167748 @default.
- W2111752017 cites W1595799286 @default.
- W2111752017 cites W2038961110 @default.
- W2111752017 cites W2043296103 @default.
- W2111752017 cites W2057429479 @default.
- W2111752017 cites W2076878770 @default.
- W2111752017 cites W2080415510 @default.
- W2111752017 cites W2411114920 @default.
- W2111752017 cites W2414030733 @default.
- W2111752017 cites W2415530480 @default.
- W2111752017 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6831405" @default.
- W2111752017 hasPublicationYear "1983" @default.
- W2111752017 type Work @default.
- W2111752017 sameAs 2111752017 @default.
- W2111752017 citedByCount "3" @default.
- W2111752017 crossrefType "journal-article" @default.
- W2111752017 hasAuthorship W2111752017A5012496556 @default.
- W2111752017 hasAuthorship W2111752017A5043198546 @default.
- W2111752017 hasAuthorship W2111752017A5084833290 @default.
- W2111752017 hasConcept C104317684 @default.
- W2111752017 hasConcept C153911025 @default.
- W2111752017 hasConcept C181199279 @default.
- W2111752017 hasConcept C185592680 @default.
- W2111752017 hasConcept C2776476023 @default.
- W2111752017 hasConcept C2776543447 @default.
- W2111752017 hasConcept C2777995097 @default.
- W2111752017 hasConcept C2778564976 @default.
- W2111752017 hasConcept C2781259782 @default.
- W2111752017 hasConcept C512185932 @default.
- W2111752017 hasConcept C55493867 @default.
- W2111752017 hasConcept C67705224 @default.
- W2111752017 hasConcept C86803240 @default.
- W2111752017 hasConceptScore W2111752017C104317684 @default.
- W2111752017 hasConceptScore W2111752017C153911025 @default.
- W2111752017 hasConceptScore W2111752017C181199279 @default.
- W2111752017 hasConceptScore W2111752017C185592680 @default.
- W2111752017 hasConceptScore W2111752017C2776476023 @default.
- W2111752017 hasConceptScore W2111752017C2776543447 @default.
- W2111752017 hasConceptScore W2111752017C2777995097 @default.
- W2111752017 hasConceptScore W2111752017C2778564976 @default.
- W2111752017 hasConceptScore W2111752017C2781259782 @default.
- W2111752017 hasConceptScore W2111752017C512185932 @default.
- W2111752017 hasConceptScore W2111752017C55493867 @default.
- W2111752017 hasConceptScore W2111752017C67705224 @default.
- W2111752017 hasConceptScore W2111752017C86803240 @default.
- W2111752017 hasIssue "4" @default.
- W2111752017 hasLocation W21117520171 @default.
- W2111752017 hasOpenAccess W2111752017 @default.
- W2111752017 hasPrimaryLocation W21117520171 @default.
- W2111752017 hasRelatedWork W1514092148 @default.
- W2111752017 hasRelatedWork W1596097154 @default.
- W2111752017 hasRelatedWork W1597643281 @default.
- W2111752017 hasRelatedWork W176424309 @default.
- W2111752017 hasRelatedWork W1979325267 @default.
- W2111752017 hasRelatedWork W2000700863 @default.
- W2111752017 hasRelatedWork W2070977761 @default.
- W2111752017 hasRelatedWork W2140200412 @default.
- W2111752017 hasRelatedWork W2141105052 @default.
- W2111752017 hasRelatedWork W2330013441 @default.
- W2111752017 hasVolume "43" @default.
- W2111752017 isParatext "false" @default.
- W2111752017 isRetracted "false" @default.
- W2111752017 magId "2111752017" @default.
- W2111752017 workType "article" @default.